Insulinoma with seizures
– a rare presentation of a rare tumour
Samartha V 1, Hegde S 2,
Philipose T.R.3
1Dr. Samartha Vinitha, Assistant Professor, 2Dr. Hegde Shreya,
Assistant Professor, Department of Pathology, A J Institute of Medical
Sciences and Research Centre, 3Dr. Philipose Thoppil Reba, Professor,
Department of Pathology, A J Institute of Medical Sciences and Research
Centre, NH -66, Kuntikan, Mangaluru, Karnataka 575004, India
Address for
correspondence: Dr Shreya Hegde, Email:
drshreyahegde@gmail.com
Abstract
Insulinoma is a rare pancreatic endocrine tumour with an incidence of 4
per million population per year and is typically sporadic, solitary and
less than 2 cms in diameter. Fewer than 5% of insulinomas are larger
than 3 cms and are more likely to be malignant. Here we report a case
of insulinoma in a female patient aged 57 years with a rare
presentation of recurrent attacks of seizures, syncope and sweating
along with episodes of hypoglycemia since 5 years. CT scan localized
the tumour to the head of the pancreas and histopathology proved the
diagnosis.
Keywords:
Insulinoma, Whipple’s triad, Seizures, Hypoglycemia
Manuscript received:
12th October 2016,
Reviewed: 25th October 2016
Author Corrected:
10th November 2016,
Accepted for Publication: 22nd November 2016
Introduction
An insulinoma is a functionally active and commonly benign endocrine
tumour of the pancreas with evidence of B-cell differentiation and
clinical symptoms of hypoglycemia due to inappropriate secretion of
insulin [1]. Pancreatic endocrine tumors are very rare
lesions with an incidence of 4 per million population per year. Of
these rare lesions, insulinomas are the most common. The majority of
patients diagnosed with an insulinoma are between 30 and 60 years of
age, with women accounting for 59% [2]. Diagnosis of this pathology
relies on clinical features along with laboratory tests, imaging
investigations to aid in localization and confirmation by
histopathological evaluation [3]. An early successful diagnosis and
excision of insulinoma will profoundly affect a patient’s
life [2].
Case
Report
We present a 57 year old female patient who presented with recurrent
episodes of syncope, sweating, seizures since 5 years. These episodes
were associated with hypoglycemia which resolved with glucose
administration. The seizures were of complex partial type for which she
received anti-epileptic treatment. She also gives a history of weight
gain, was diagnosed of hypothyroidism 2 years back and is on medication
for the same. The other routine blood investigations were normal.
Ultrasound abdomen showed moderate fatty liver changes. CT scan of the
abdomen revealed a well defined moderately enhancing lesion measuring
13x11mm in the head of the pancreas. Rest of the pancreas appeared
normal. A provisional diagnosis of Insulinoma was suggested. The lesion
was excised and sent for histopathology.
Gross examination of the fibrofatty lesion measuring 2.5x2x1.5cms
revealed a well circumscribed yellow brown area measuring 1 cm on the
cut surface.
On microscopic examination, an encapsulated tumour composed of
pleomorphic cells with finely granular cytoplasm and ill-defined
cytoplasmic borders was noted. The tumour cells were seen arranged in
trabecular and glandular pattern separated by vascular stroma. The
nuclei were highly pleomorphic, vesicular with 1-2 nucleoli. (Fig 1,2).
Sparse mitosis with few apoptotic bodies were seen. The normal
pancreatic tissue was seen at the edge of the tumour. A histological
diagnosis of pancreatic endocrine tumour (Insulinoma) was made. Since
there was no unequivocal evidence of malignancy in the form of cellular
anaplasia or infiltration of adjacent organs, long clinical follow up
even after surgical excision was advised.
Discussion
Insulinomas account for 60% of islet cell tumors and are typically
hypervascular, solitary, small tumors, 90% of which measure less than 2
cm and 30% measure less than 1 cm in diameter. Almost all
insulinomas are located within the pancreas, even though aberrant cases
have been described in the duodenum, ileum, lung and cervix.
Approximately 10% are multiple, 10% are malignant and 4-7% are
associated with MEN 1. Insulinomas are diagnosed over a wide age group
range, but rarely before the age of 15. The peak incidence is found
between 40 and 60 years [4].
The etiology and pathogenesis of insulinomas are unknown. No risk
factors have been associated with these tumors. Embryologically,
pancreatic tumors arise from similar precursor cells as pancreatic
islet cells which are derived from the endoderm [2].
The tumour is characterized by endogenous hypersecretion of insulin and
the subsequent development of symptoms. Symptoms of hypoglycemia
include both neurogenic symptoms from adrenergic as well as cholinergic
stimulation and neuroglycopenic symptoms as a direct result of a
decrease in brain substrate. Signs and symptoms include diaphoresis,
warmth, hunger, weakness, tingling sensations, paresthesia, difficulty
in thinking, confusion, tremulousness, tiredness, drowsiness,
palpitations, tachycardia, dizziness, nervousness, anxiety, blurred
vision, stupor or coma [5]. The Whipple triad includes:
symptoms of hypoglycemia, plasma glucose levels < 3 mmol / litre
and relief of symptoms with administration of glucose [2].
Figure-1: Photomicrograph
showing tumour cells arranged in trabecular and glandular pattern
separated by stroma (10x)
Figure-2:
Photomicrograph showing tumour cells with finely granular cytoplasm and
pleomorphic vesicular nuclei (40x)
The diagnosis of insulinoma is suggested by endogenous hyperinsulinemia
in the presence of hypoglycemia and reversal of the symptoms by the
administration of glucose [5]. In patients with insulinoma, there is
continued secretion of insulin despite a lower glucose level. Insulin
is synthesized as a single chain precursor, proinsulin - which is
cleaved into a C-peptide and insulin, both of which are secreted in
equimolar concentrations [6].
Once the biochemical diagnosis of a probable insulinoma has been
established, localization investigations can greatly aid management
decisions. Non invasive methods such as abdominal ultrasound, CT
scanning and MRI have the advantage of being simple and quick to
perform [7].
The majorities of insulinomas is located in the pancreas or are
directly attached to it. Compiled data indicate that insulinomas are
equally distributed between the head, body and tail of the pancreas
with a slight predominance in the head and tail region [8]. Grossly,
insulinomas are well circumscribed, softer than the surrounding
pancreatic parenchyma and have red brown cut surface. Insulinomas are
frequently discovered while still small with 75% of the tumors
measuring 0.5-2 cm in diameter and less than 2 g in weight. The
reported diameter ranges from 0.5 – 11 cm. Tumour size is
unrelated to severity of symptoms. Malignant insulinomas may show gross
local invasion of peripancreatic fatty tissue and / or adjacent organs
such as the duodenum or the spleen. The first metastases are usually
found in the regional lymph nodes (peripancreatic, celiac, periaortic)
and the liver. Spread to other distant sites is unusual [2].
Microscopically, insulinomas exhibit four main histological patterns -
solid, trabecular, gland-like tumour growth and mixed forms. Larger
tumors are encapsulated but the capsule is usually incomplete. Smaller
tumors and microadenomas are rarely encapsulated. Tumor cells
frequently exhibit a bland cytology and cells with large, pleomorphic
nuclei are rare. If present, these features are not predictive of
malignant behavior. A relatively uncommon, but characteristic finding
in insulinoma is the deposition of amyloid [9]. Almost all insulinomas
exhibit immunoreactivity for insulin and proinsulin. The intensity and
extent of this immunoreactivity does not correlate with circulating
insulin levels [2].
Conclusion
Insulinoma is reported to be the most common cause of hypoglycemia in
patients who are well without systemic illness, once factitious
hypoglycemia has been excluded [10]. Early diagnosis and
confirmation by histopathology is essential to prevent lethal
hypoglycemia [3].
Funding:
Nil, Conflict of
interest: None initiated.
Permission from IRB:
Yes
References
1. Grant CS. Surgical aspects of hyperinsulinemic hypoglycemia.
Endocrinol Metab Clin North Am. 1999 Sep;28(3):533–54. DOI;
10.1016/s0889-8529(05)70087-6. [PubMed]
2. Komminoth P, Perren A, Oberg K, Rindi G, Heitz U, Kloppel
G. Insulinoma. In:Ronald A, De Lellis, Richardo VL, Phillip UH, eds.
WHO Classification of Tumors- Endocrine organs. Lyon:IARC Press;2004.
p183-6.
3. Patel S, Narwaria M, Parekh D, Shah V. Insulinoma : Case report and
review of diagnostic and treatment modalities. J Assoc Physicians
India. 2013;61:423-6. [PubMed]
4. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol
Metab Clin North Am. 1989 Mar;18(1):45-74. [PubMed]
5. Zografos GN ,Stathopoulou A, Mitropapas G, Karoubalis J,
Kontogeorgos G, Kaltsas G, et al. Preoperative imaging and localization
of small sized insulinoma with EUS-guided fine needle tattoing:a case
report. Hormones. 2005;4(2):111-6. [PubMed]
6. Roith DL. Tumor induced hypoglycemia. N Engl J Med. 1999
Sep;341(10):757-8. DOI:10.1056/NEJM199909023411011. [PubMed]
7. Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, et al
.CT, endoscopic sonography, and a combined protocol for preoperative
evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003
Oct;181(4):987-92. DOI : 10.2214/ajr.181.4.1810987.
8. Filipi CJ, Higgins GA. Diagnosis and management of insulinoma. Am
J Surg. 1973 Feb;125(2):231-9. [PubMed]
9. Williams AJ, Coates PJ, Lowe DG, McLean C, Gale EA.
Immunohistochemical investigation of insulinomas for islet amyloid
polypeptide and insulin : evidence for differential synthesis and
storage. Histopathology. 1992 Sep;21(3):215-23. DOI :
10.1111/j.1365-2559.1992.tb00379.x.
10. Druce MR, Muthuppalaniappan VM, O’Leary B, Chew SL, Drake
WM, Monson JP, et al. Diagnosis and localization of
insulinoma:the value of modern magnetic resonance imaging in
conjunction with calcium stimulation catheterization. Eur J Endocrinol.
2010 May;162(5):971-8. DOI : 10.1530/EJE-10-0056.
How to cite this article?
Samartha V, Hegde S, Philipose T.R.Insulinoma with seizures –
a rare presentation of a rare tumour.Int J Med Res Rev
2016;4(11):1975-1977.doi:10.17511/ijmrr. 2016.i11.12.